參考文獻 |
Akira, S. 2003. ′Toll-like receptor signaling′, J Biol Chem, 278: 38105-8.
Aronoff, D. M., C. Canetti, C. H. Serezani, M. Luo, and M. Peters-Golden. 2005. ′Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1′, J Immunol, 174: 595-9.
Banchereau, J., and R. M. Steinman. 1998. ′Dendritic cells and the control of immunity′, Nature, 392: 245-52.
Beard, M. B., A. E. Olsen, R. E. Jones, S. Erdogan, M. D. Houslay, and G. B. Bolger. 2000. ′UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions′, J Biol Chem, 275: 10349-58.
Busillo, J. M., and J. L. Benovic. 2007. ′Regulation of CXCR4 signaling′, Biochim Biophys Acta, 1768: 952-63.
Calverley, P. M., K. F. Rabe, U. M. Goehring, S. Kristiansen, L. M. Fabbri, F. J. Martinez, M, and M. study groups. 2009. ′Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials′, Lancet, 374: 685-94.
Castro, A., M. J. Jerez, C. Gil, and A. Martinez. 2005. ′Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors′, Med Res Rev, 25: 229-44.
Clark, G. J., N. Angel, M. Kato, J. A. Lopez, K. MacDonald, S. Vuckovic, and D. N. Hart. 2000. ′The role of dendritic cells in the innate immune system′, Microbes Infect, 2: 257-72.
Conti, M., and J. Beavo. 2007. ′Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling′, Annu Rev Biochem, 76: 481-511.
Corbin, J. D., I. V. Turko, A. Beasley, and S. H. Francis. 2000. ′Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities′, Eur J Biochem, 267: 2760-7.
Delgado-Martin, C., C. Escribano, J. L. Pablos, L. Riol-Blanco, and J. L. Rodriguez-Fernandez. 2011. ′Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells′, J Biol Chem, 286: 37222-36.
Domanska, U. M., R. C. Kruizinga, W. B. Nagengast, H. Timmer-Bosscha, G. Huls, E. G. de Vries, and A. M. Walenkamp. 2013. ′A review on CXCR4/CXCL12 axis in oncology: no place to hide′, Eur J Cancer, 49: 219-30.
Fan Chung, K. 2006. ′Phosphodiesterase inhibitors in airways disease′, Eur J Pharmacol, 533: 110-7.
Feil, C., and H. G. Augustin. 1998. ′Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines′, Biochem Biophys Res Commun, 247: 38-45.
Francis, S. H., M. A. Blount, and J. D. Corbin. 2011. ′Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions′, Physiol Rev, 91: 651-90.
Gagliardi, M. C., and M. T. De Magistris. 2003. ′Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression′, Vaccine, 21: 856-61.
Galgani, M., V. De Rosa, S. De Simone, A. Leonardi, U. D′Oro, G. Napolitani, A. M. Masci, S. Zappacosta, and L. Racioppi. 2004. ′Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling′, J Biol Chem, 279: 32507-14.
Garay, J., J. A. D′Angelo, Y. Park, C. M. Summa, M. L. Aiken, E. Morales, K. Badizadegan, E. Fiebiger, and B. L. Dickinson. 2010. ′Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells′, J Immunol, 185: 3227-38.
Gasperini, S., L. Crepaldi, F. Calzetti, L. Gatto, C. Berlato, F. Bazzoni, A. Yoshimura, and M. A. Cassatella. 2002. ′Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal′, Eur Cytokine Netw, 13: 47-53.
Giembycz, M. A., C. J. Corrigan, J. Seybold, R. Newton, and P. J. Barnes. 1996. ′Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2′, Br J Pharmacol, 118: 1945-58.
Giordano, D., D. M. Magaletti, E. A. Clark, and J. A. Beavo. 2003. ′Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells′, J Immunol, 171: 6421-30.
Gloerich, M., and J. L. Bos. 2010. ′Epac: defining a new mechanism for cAMP action′, Annu Rev Pharmacol Toxicol, 50: 355-75.
Goraya, T. A., and D. M. Cooper. 2005. ′Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives′, Cell Signal, 17: 789-97.
Gupta, S. K., P. G. Lysko, K. Pillarisetti, E. Ohlstein, and J. M. Stadel. 1998. ′Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines′, J Biol Chem, 273: 4282-7.
Hertz, A. L., and J. A. Beavo. 2011. ′Cyclic nucleotides and phosphodiesterases in monocytic differentiation′, Handb Exp Pharmacol: 365-90.
Hespel, C., and M. Moser. 2012. ′Role of inflammatory dendritic cells in innate and adaptive immunity′, Eur J Immunol, 42: 2535-43.
Heystek, H. C., A. C. Thierry, P. Soulard, and C. Moulon. 2003. ′Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity′, Int Immunol, 15: 827-35.
Houslay, M. D., and G. S. Baillie. 2003. ′The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways′, Biochem Soc Trans, 31: 1186-90.
Jin, S. L., and M. Conti. 2002. ′Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses′, Proc Natl Acad Sci U S A, 99: 7628-33.
Jin, S. L., S. L. Ding, and S. C. Lin. 2012. ′Phosphodiesterase 4 and its inhibitors in inflammatory diseases′, Chang Gung Med J, 35: 197-210.
Jin, S. L., S. Goya, S. Nakae, D. Wang, M. Bruss, C. Hou, D. Umetsu, and M. Conti. 2010. ′Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma′, J Allergy Clin Immunol, 126: 1252-9 e12.
Jin, S. L., L. Lan, M. Zoudilova, and M. Conti. 2005. ′Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages′, J Immunol, 175: 1523-31.
Jin, S. L., J. V. Swinnen, and M. Conti. 1992. ′Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain′, J Biol Chem, 267: 18929-39.
Jin, S. LCatherine, Yi-Ling Chen, Shiau-Li Ding, Marco Conti, Ciou-Rong Lai, Huan-Chu Lo, Jing-Xing Yang, Hsian-He Hsu, and Chin-Pyng Wu. 2015. ′Phosphodiesterase 4b is essential for lipopolysaccharide-induced CC chemokine ligand 3 production in mouse macrophages′, Journal of Medical Sciences, 35: 111.
Jourdan, P., J. P. Vendrell, M. F. Huguet, M. Segondy, J. Bousquet, J. Pene, and H. Yssel. 2000. ′Cytokines and cell surface molecules independently induce CXCR4 expression on CD4+ CCR7+ human memory T cells′, J Immunol, 165: 716-24.
Kabashima, K., N. Shiraishi, K. Sugita, T. Mori, A. Onoue, M. Kobayashi, J. Sakabe, R. Yoshiki, H. Tamamura, N. Fujii, K. Inaba, and Y. Tokura. 2007. ′CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells′, Am J Pathol, 171: 1249-57.
Kambayashi, T., R. P. Wallin, and H. G. Ljunggren. 2001. ′cAMP-elevating agents suppress dendritic cell function′, J Leukoc Biol, 70: 903-10.
Kammer, G. M. 1988. ′The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response′, Immunol Today, 9: 222-9.
Kenan, Y., T. Murata, Y. Shakur, E. Degerman, and V. C. Manganiello. 2000. ′Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms′, J Biol Chem, 275: 12331-8.
Kobilka, B. K., and X. Deupi. 2007. ′Conformational complexity of G-protein-coupled receptors′, Trends Pharmacol Sci, 28: 397-406.
Kovala, T., B. D. Sanwal, and E. H. Ball. 1997. ′Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants′, Biochemistry, 36: 2968-76.
Lenhard, J. M., D. B. Kassel, W. J. Rocque, L. Hamacher, W. D. Holmes, I. Patel, C. Hoffman, and M. Luther. 1996. ′Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase′, Biochem J, 316 ( Pt 3): 751-8.
Li, H. S., C. Y. Yang, K. C. Nallaparaju, H. Zhang, Y. J. Liu, A. W. Goldrath, and S. S. Watowich. 2012. ′The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development′, Blood, 120: 4363-73.
Lim, J., G. Pahlke, and M. Conti. 1999. ′Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain′, J Biol Chem, 274: 19677-85.
Liu, Y., and G. Shi. 2014. ′Role of G protein-coupled receptors in control of dendritic cell migration′, Biomed Res Int, 2014: 738253.
Loza, M. J., S. Foster, S. P. Peters, and R. B. Penn. 2006. ′Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells′, Blood, 107: 2052-60.
Maldonado-Arocho, F. J., and K. A. Bradley. 2009. ′Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta′, Infect Immun, 77: 2036-42.
Merad, M., P. Sathe, J. Helft, J. Miller, and A. Mortha. 2013. ′The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting′, Annu Rev Immunol, 31: 563-604.
Moll, H. 2003. ′Dendritic cells and host resistance to infection′, Cell Microbiol, 5: 493-500.
Muradov, H., K. K. Boyd, and N. O. Artemyev. 2004. ′Structural determinants of the PDE6 GAF A domain for binding the inhibitory gamma-subunit and noncatalytic cGMP′, Vision Res, 44: 2437-44.
Omori, K., and J. Kotera. 2007. ′Overview of PDEs and their regulation′, Circ Res, 100: 309-27.
Papp, K., K. Reich, C. L. Leonardi, L. Kircik, S. Chimenti, R. G. Langley, C. Hu, R. M. Stevens, R. M. Day, K. B. Gordon, N. J. Korman, and C. E. Griffiths. 2015. ′Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)′, J Am Acad Dermatol, 73: 37-49.
Pifferi, S., A. Boccaccio, and A. Menini. 2006. ′Cyclic nucleotide-gated ion channels in sensory transduction′, FEBS Lett, 580: 2853-9.
Rennard, S. I., P. M. Calverley, U. M. Goehring, D. Bredenbroker, and F. J. Martinez. 2011. ′Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD′, Respir Res, 12: 18.
Ricart, B. G., B. John, D. Lee, C. A. Hunter, and D. A. Hammer. 2011. ′Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4′, J Immunol, 186: 53-61.
Rich, T. C., T. E. Tse, J. G. Rohan, J. Schaack, and J. W. Karpen. 2001. ′In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors′, J Gen Physiol, 118: 63-78.
Richter, W., and M. Conti. 2002. ′Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs)′, J Biol Chem, 277: 40212-21.
Sadhu, C., H. J. Ting, B. Lipsky, K. Hensley, L. F. Garcia-Martinez, S. I. Simon, and D. E. Staunton. 2007. ′CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity′, J Leukoc Biol, 81: 1395-403.
Saini, V., A. Marchese, and M. Majetschak. 2010. ′CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin′, J Biol Chem, 285: 15566-76.
Sassone-Corsi, P. 2012. ′The cyclic AMP pathway′, Cold Spring Harb Perspect Biol, 4.
Serezani, C. H., M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden. 2008. ′Cyclic AMP: master regulator of innate immune cell function′, Am J Respir Cell Mol Biol, 39: 127-32.
Sette, C., and M. Conti. 1996. ′Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation′, J Biol Chem, 271: 16526-34.
Shakur, Y., L. S. Holst, T. R. Landstrom, M. Movsesian, E. Degerman, and V. Manganiello. 2001. ′Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family′, Prog Nucleic Acid Res Mol Biol, 66: 241-77.
Skalhegg, B. S., B. F. Landmark, S. O. Doskeland, V. Hansson, T. Lea, and T. Jahnsen. 1992. ′Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes′, J Biol Chem, 267: 15707-14.
Villablanca, E. J., V. Russo, and J. R. Mora. 2008. ′Dendritic cell migration and lymphocyte homing imprinting′, Histol Histopathol, 23: 897-910.
Wang, J., E. Guan, G. Roderiquez, V. Calvert, R. Alvarez, and M. A. Norcross. 2001. ′Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages′, J Biol Chem, 276: 49236-43. |